Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 15 for:    Hydrochlorothiazide AND metoprolol succinate

Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000620
Recruitment Status : Completed
First Posted : October 28, 1999
Results First Posted : September 15, 2014
Last Update Posted : November 22, 2016
Sponsor:
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Aging (NIA)
National Eye Institute (NEI)
Centers for Disease Control and Prevention
Information provided by (Responsible Party):
National Heart, Lung, and Blood Institute (NHLBI)

Tracking Information
First Submitted Date  ICMJE October 27, 1999
First Posted Date  ICMJE October 28, 1999
Results First Submitted Date  ICMJE September 5, 2014
Results First Posted Date  ICMJE September 15, 2014
Last Update Posted Date November 22, 2016
Study Start Date  ICMJE September 1999
Actual Primary Completion Date June 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 5, 2014)
  • First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial. [ Time Frame: 4.9 years ]
    Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial). In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion.
  • First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial. [ Time Frame: 4.7 years ]
    Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial.
  • First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial. [ Time Frame: 4.7 years ]
    Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants.
Original Primary Outcome Measures  ICMJE Not Provided
Change History Complete list of historical versions of study NCT00000620 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: September 5, 2014)
  • Death From Any Cause in the Glycemia Trial. [ Time Frame: 4.9 years ]
    Time to death from any cause. Secondary measure for Glycemia Trial. A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid).
  • Stroke in the Blood Pressure Trial. [ Time Frame: 4.7 years ]
    Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial.
  • First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial. [ Time Frame: 4.7 years ]
    Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants.
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Official Title  ICMJE Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
Detailed Description

BACKGROUND:

Currently, about 17 million Americans have been diagnosed with diabetes and more than 90 percent of them have type 2 diabetes. The number of people with this form of diabetes, formerly known as adult onset or non-insulin dependent diabetes, is growing rapidly. By 2050, the number of Americans with diagnosed diabetes is projected to increase by 165 percent to 29 million, of whom 27 million will have the type 2 form. Cardiovascular disease (CVD) is the leading cause of death in people with type 2 diabetes; these individuals die of CVD at rates two to four times higher than those who do not have diabetes. They also experience more nonfatal heart attacks and strokes.

Type 2 diabetes is associated with older age and is more common in those who are overweight or obese and have a family history of diabetes. Women with a history of diabetes during pregnancy, adults with impaired glucose tolerance, people with a sedentary lifestyle, and members of a minority race/ethnicity are also at a greater risk for developing type 2 diabetes. African Americans, Hispanic/Latino Americans, American Indians, and some Asian Americans and Pacific Islanders are at particularly high risk for type 2 diabetes.

DESIGN NARRATIVE:

The three strategies tested in ACCORD included the following: (1) Blood sugar - ACCORD was designed to determine whether lowering blood glucose to a level closer to normal than called for in current guidelines reduces CVD risk. The study estimated effects on CVD of that level compared with a level that is usually targeted. (2) Blood pressure - many people with type 2 diabetes have high blood pressure. The blood pressure part of the trial was designed to determine the effects of lowering blood pressure in the context of good blood sugar control, that is to determine whether lowering blood pressure to normal (systolic pressure less than 120 mm Hg) will better reduce CVD risk, as compared to a usually-targeted level in current clinical practice (i.e., below the definition of hypertension; systolic pressure less than 140 mm Hg). (3) Blood Fats - Many people with diabetes have high levels of LDL ("bad") cholesterol and triglycerides, as well as low levels of HDL ("good") cholesterol. ACCORD participants who are selected for this part of the trial were assigned to an intervention to improve blood fat levels. This part of the study looked at the effects of lowering LDL cholesterol and blood triglycerides and increasing HDL cholesterol compared to an intervention that only lowers LDL cholesterol, all in the context of good blood sugar control. A drug from a class of drugs called "fibrates" was used to lower triglycerides and increase HDL cholesterol, whereas a drug from the class of drugs called "statins" was used to lower LDL cholesterol.

All ACCORD participants received blood sugar treatment from the study. Based on the second trial (Blood Pressure or Lipid) they were assigned to, participants also received their high blood pressure or cholesterol care from the study. Study participants received all medication and treatments related to the study free of charge. Individuals who selected for and consented to participate in the ACCORD study continued to see their personal physician for all other health care.

In summary, the ACCORD Study was a double 2x2 factorial design with factors consisting of: intensive versus standard glycemic control, intensive versus standard blood pressure control, and blinded fenofibrate or placebo in combination with simvastatin to maintain desirable LDL-C levels. All 10,251 participants were randomized to the glycemic interventions; a subgroup of 4,733 participants who met the blood pressure entry criteria were randomized to the blood pressure interventions in one 2x2 trial; and a distinct subgroup of 5,518 participants who met the lipid entry criteria were randomized to the lipid interventions in the second 2x2 trial. All participants had established type 2 diabetes and were recruited from 77 clinical centers in the United States (64 sites) and Canada (13 sites).

On February 6, 2008, the National Heart, Lung and Blood Institute (NHLBI) announced that participants in the intensive glycemia treatment would be transitioned to the ACCORD standard glycemic treatment approach due to higher mortality in the intensive treatment group terminating the experimental arm of the Glycemia Trial early. The Blood Pressure and Lipid trials continued as designed to their planned termination in 2009.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE
  • Atherosclerosis
  • Cardiovascular Diseases
  • Hypercholesterolemia
  • Hypertension
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus
  • Coronary Disease
Intervention  ICMJE
  • Drug: Anti-hyperglycemic Agents
    Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control <6%; standard control 7.0-7.9%).
    Other Names:
    • glimepiride (Amaryl)
    • metformin (Glucophage)
    • repaglinide (Gluconorm, Prandin)
    • rosiglitazone (Avandia)
    • pioglitazone (Actos)
    • human regular insulin (Novolin ge Toronto)
    • human NPH (Novolin N)
    • human mixed (Novolin 70/30)
    • human isophane (Novolin ge NPH)
    • human 30/70 (Novolin ge 30/70)
    • insulin aspart (NovoRapid, NovoLog)
    • insulin detemir (Levemir)
    • human regular insulin (Novolin R)
    • insulin glargine (Lantus)
    • Acarbose
  • Drug: Anti-hypertensive Agents
    Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control <120 mm Hg; standard control <140 mm Hg).
    Other Names:
    • benazepril (Lotensin, Zestril, Altace)
    • chlorthalidone (Thalitone)
    • metoprolol (Toprol XL)
    • diltiazem (Tiazac)
    • plendil (Felodipine)
    • terazosin (Hytrin)
    • candesartan (Atacand)
    • valsartan (Diovan)
    • furosemide
    • reserpine
    • hydralazine
    • carvedilol (Coreg)
    • triamterene / hydrochlorothiazide (Dyazide)
    • metoprolol / hydrochlorothiazide(Lopressor HCT)
    • benazepril / hydrochlorothiazide (Lotensin HCT)
    • lisinopril / hydrochlorothiazide (Zestoretic)
    • candesartan / hydrochlorothiazide (Atacand HCT)
    • valsartan / hydrochlorothiazide (Diovan HCT)
    • amlodipine / benazepril (Lotrel)
  • Drug: Blinded fenofibrate or placebo plus simvastatin
    Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR <50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
    Other Name: fenofibrate (Tricor)
Study Arms  ICMJE
  • Experimental: Glycemia Trial: intensive control
    Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels <6.0%.
    Intervention: Drug: Anti-hyperglycemic Agents
  • Active Comparator: Glycemia Trial: standard control
    Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 - 7.9%.
    Intervention: Drug: Anti-hyperglycemic Agents
  • Experimental: BP Trial: intensive control
    Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to <120 mmHg.
    Intervention: Drug: Anti-hypertensive Agents
  • Active Comparator: BP Trial: standard control
    Open label administration of multiple anti-hypertensive agents to maintain SBP level <140 mm Hg.
    Intervention: Drug: Anti-hypertensive Agents
  • Experimental: Lipid Trial: fenofibrate
    Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
    Intervention: Drug: Blinded fenofibrate or placebo plus simvastatin
  • Placebo Comparator: Lipid Trial: placebo
    Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m2 or 54 mg/day in participants with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
    Intervention: Drug: Blinded fenofibrate or placebo plus simvastatin
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 7, 2008)
10251
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE December 2012
Actual Primary Completion Date June 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosed with type 2 diabetes mellitus, as determined by the new American Diabetes Association guidelines, which include a fasting plasma glucose level greater than 126 mg/dl (7.0 mmol/l), or a 2-hour postload value in the oral glucose tolerance test of greater than 200 mg/dl, with confirmation by a retest
  • For participants aged 40 years or older, history of CVD (heart attack, stroke, history of coronary revascularization, history of peripheral or carotid revascularization, or demonstrated angina)
  • For participants aged 55 years or older, a history of CVD is not required, but participant must be considered to be at high risk for experiencing a CVD event due to existing CVD, subclinical disease, or 2+ CVD risk factors
  • HbA1c 7.5%-9% (if on more drugs) or 7.5%-11% (if on fewer drugs)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 40 Years to 79 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00000620
Other Study ID Numbers  ICMJE 123
N01HC95178 ( U.S. NIH Grant/Contract )
N01HC95179 ( U.S. NIH Grant/Contract )
N01HC95180 ( U.S. NIH Grant/Contract )
N01HC95181 ( U.S. NIH Grant/Contract )
N01HC95182 ( U.S. NIH Grant/Contract )
N01HC95183 ( U.S. NIH Grant/Contract )
N01HC95184 ( U.S. NIH Grant/Contract )
IAA#Y1HC9035 ( Other Grant/Funding Number: U.S. Centers for Disease Control )
IAA#Y1HC1010 ( Other Grant/Funding Number: U.S. Centers for Disease Control )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party National Heart, Lung, and Blood Institute (NHLBI)
Study Sponsor  ICMJE National Heart, Lung, and Blood Institute (NHLBI)
Collaborators  ICMJE
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Institute on Aging (NIA)
  • National Eye Institute (NEI)
  • Centers for Disease Control and Prevention
Investigators  ICMJE
Study Director: Denise Simons-Morton, MD, PhD National Heart, Lung, and Blood Institute (NHLBI)
Study Chair: William Friedewald, MD Columbia University, New York, NY
Principal Investigator: Robert Byington, PhD Wake Forest University, Winston-Salem, NC
PRS Account National Heart, Lung, and Blood Institute (NHLBI)
Verification Date November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP